As of March 31, 2023, the Ontario Drug Benefit (ODB) program’s Biosimilar Policy requires eligible Ontarians receiving coverage for some originator biologic drugs (Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan®) to transition to their biosimilar versions by December 28, 2023 unless they qualify for an exemption. Pharmacists play an important role in addressing patient […]
This page is only available to members. log in become a member